



(11) **EP 2 395 012 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) Int Cl.:
A61K 48/00 ^(2006.01) **A61K 31/713** ^(2006.01)
C12N 15/113 ^(2010.01) **A61K 9/127** ^(2006.01)
C12N 15/11 ^(2006.01)

(48) Corrigendum issued on:
06.06.2018 Bulletin 2018/23

(45) Date of publication and mention
of the grant of the patent:
18.04.2018 Bulletin 2018/16

(21) Application number: **11169865.0**

(22) Date of filing: **02.11.2006**

(54) **Modified siRNA molecules and uses thereof**

Modifizierte siRNA-Moleküle und Verwendungen davon

Molécules d'ARNsi modifiées et leurs utilisations

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI
SK TR

(30) Priority: **02.11.2005 US 732964 P**
30.06.2006 US 817933 P

(43) Date of publication of application:
14.12.2011 Bulletin 2011/50

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
06804676.2 / 1 948 674

(73) Proprietor: **Arbutus Biopharma Corporation**
Vancouver BC V7Y 1B3 (CA)

(72) Inventors:
• **MacLachan, Ian**
Mission, British Columbia V4S 1E5 (CA)
• **Judge, Adam**
Vancouver, British Columbia V6J 2C6 (CA)

(74) Representative: **J A Kemp**
14 South Square
Gray's Inn
London WC1R 5JJ (GB)

(56) References cited:
WO-A-2004/029212 WO-A-2004/046324
WO-A2-2004/090105 US-A1- 2005 119 214

- **MORRISSEY DAVID V ET AL: "Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 23, no. 8, 1 August 2005 (2005-08-01), pages 1002-1007, XP002452540, ISSN: 1087-0156**
- **HORNUNG V ET AL: "Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7", NATURE MEDICINE, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 11, no. 3, 20 February 2005 (2005-02-20), pages 263-270, XP002371477, ISSN: 1078-8956, DOI: 10.1038/NM1191**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 395 012 B8